Irish based Arran Chemical Company, has responded to client demand for the provision of fine chemicals, pharmaceutical intermediates and advanced building blocks by implementation of its three stage ADAPT (Arran Deploys Advanced Production Technologies) strategy through a multi-million Euro investment.
The investment is focused around increasing capacity, further application of its selectAZyme biocatalysis technology and implementation of flow chemistry. Arran is proud to announce the completion of Stage II of the strategy and the positive benefit to its global client base.
Following acquisition by the Almac Group in November 2015, Arran has completed a sustained programme of investment in people and infrastructure to meet growing product diversity and production demands.
As reported in 2017, Arran’s manufacturing plant assets have been upgraded bringing total manufacturing capacity to approximately 85 m3 with vessels ranging from kilo laboratory scale to 8 m3. The final phase of investment will involve the introduction of specialist flow manufacturing technologies.
“With the completion of Stage II of our ADAPT strategy, we deliver on our promise to our clients to offer solutions which are economically sound, safe, scalable and high quality through the application of new capacity and enzyme technology.” said Prof Tom Moody, VP Technology Development and Commercialisation, Arran Chemical Company.
“We are determined to remain at the forefront of innovation to ensure our customers receive best-in-class solutions with uninterrupted supply. This will be further augmented with the initiation of Stage III and subsequent build of flow chemistry capabilities.”
Visit Arran Chemical Company at CPhI on stand 1J53.